

Index

- abortion, ECHR, 287–88
- abuse of dominant position
 - AstraZeneca, 655–59
 - competition law, 358–62, 364–65, 655–59, 666
 - generic competition, 655–59, 666
 - GlaxoSmithKline, 666
 - services of general economic interest (SGEI), 364–65
- advertising ban
 - Tobacco Advertising Directive, 99–100
 - tobacco control, 99–100, 262–65
- After the Services Directive, governance, 121–28
- agencies, *see also* regulatory agencies; supranational agencies
 - EU, 150
 - European Union Agency for Fundamental Rights, 308–12
 - key area, EU legal and policy developments in health, 45–49
 - overview, 45–49
 - risk analysis, 165
- aims, this book's, 1
- Altmark package
 - public procurement, 384–89, 396–97
 - state aid, 384–89
- ambulance services, public procurement, 397–98
- 'amenable mortality', policy, 5
- anti-competitive agreements
 - Commission Inquiry, 660–61
 - generic competition, 660–61
- AstraZeneca
 - abuse of dominant position, 655–59
 - competition law, 655–59
 - regulatory pathway, 655–59
- award procedures
 - closed awards, 413–14
 - competitive awards, 415–16
 - no contractual relationship, 412–13
 - open awards, 414–15
 - public procurement, 412–16
- balance, need for, 83
- barriers, free movement of services, 468–77
- Bettercare* case, competition law, 345–46
- Biomedicine Convention, health care law, 285–86
- bio-similar medicines/products, generic competition, 653–55
- Blood Safety Directive, public health policy, 238–39
- Bolkestein Directive
 - governance, 121–28
 - Netherlands, 431–33
 - private health insurance, 431–33
- border regions access, treatment abroad, 538–40
- 'brain drain'
 - ethical recruitment guidelines, 622–23
 - health professionals, 622–23
- budget, public health policy, 90–92
- BUPA
 - financial transfers, 440–45
 - Ireland, 440–45
 - risk equalization schemes, 440–45
- CAP, *see* Common Agricultural Policy
- cartels
 - competition law, 350–58
 - exclusions, 355–58

- case-law
 - ECJ, 516–21
 - free movement of patients, 516–21
- centralized/decentralized licensing regime, pharmaceuticals market, 644–46
- CFI, *see* Court of First Instance
- challenges
 - policy, 4–19
 - supranational solidarity, 22–24
 - variety in approaches, 22
 - welfare, 22–24
- Charter of Fundamental Rights of the European Union, *see* EU Charter
- client politics (diffuse/concentrated), 8–9
- clinical trials
 - patent protection, 647–48
 - pharmaceuticals market, 647–48
- closed awards, award procedures, public procurement, 413–14
- Commission Inquiry
 - anti-competitive agreements, 660–61
 - generic competition, 659–61
 - patent protection, 659–61
- Commission's role, new governance, 226–28
- Committee for Proprietary Medicinal Products (CPMP)
 - health protection, 158–59
 - pharmaceuticals policy and law, 158–59
- Common Agricultural Policy (CAP), public health policy, 234
- common health care objectives
 - new governance, 207
 - OMC, 207
- common values and principles, policy, 14–18
- communicable disease control
 - ECDC, 252–56
 - goods, restrictions on movements, 249–50
 - IHR, 247–49
 - networks, EU, 254–55
 - people, restrictions on movements, 250–51
 - public health policy, 247–57
 - restrictions on movements of goods, 249–50
 - restrictions on movements of
 - people, 250–51
 - summary, 256–57
 - surveillance/response system, 251–56
- communication, health professionals, 599–600
- community framework
 - free movement of patients, 551–56, 558–59
 - safe, high-quality, efficient care, 551–56, 558–59
- competition
 - competition policy 'toolkit', 638–39
 - consequences, 642–44
 - intra-brand competition, 642, 662–63
 - parameters, 640–44
 - pharmaceuticals market, 635–38
 - policy, 25
- competition law, 337–78
 - abuse of dominant position, 358–62, 364–65, 655–59, 666
 - applying, 338–49
 - AstraZeneca, 655–59
 - Bettercare* case, 345–46
 - cartels, 350–58
 - Commission Inquiry, 659–61
 - conclusions, 334–36, 376–78
 - Constitutional Treaty, 332–34
 - damage claims, 374–76
 - decentralization of enforcement, 670–72
 - ECJ, 30–32, 322–25
 - economic activity, 319
 - e-health, 571–72
 - enforcement, 367–76
 - enforcement analysis, 368–69
 - European Commission, 330–34
 - exclusion, social solidarity, 320–25
 - exclusionary abuse, 359–62
 - Finnish Competition Authority (FCA), 347
 - Foundation Trusts (FTs), 346–47
 - free movement of services, 101–2
 - fundholding scheme, UK, 344–45
 - generic medicines, 655–59
 - German Competition Authority (GCA), 347–48
 - health insurance market, 365–67
 - health insurers, 342

- health policy, 337–78
- health providers, 342
- health system reforms, 372–73
- imperium* principle, 341
- internal market, 101–2
- key area, EU legal and policy
 - developments in health, 57–62
- legal crossroads, 338–39
- markets, 315–18
- NCAs, 367–76, 377
- Netherlands, 372–73
- overview, 57–62
- pharmaceuticals market, 655–59
- pharmaceuticals pricing, 373
- political reform, 330–34
- predatory pricing, 360–62
- privatization, 340–41
- prohibited conduct, 350–67
- public services, 315–36
- public/private sectors, 344–48
- scope, 319–25
- SGEI, 325–29, 362–67
- social insurance institutions, 343
- social solidarity exclusion, 315–18, 320–25
- state regulation, 362–67
- competition parameters,
 - pharmaceuticals market, 640–44
- competition types, pharmaceuticals market, 640–44
- competitive awards, award procedures, public procurement, 415–16
- complementary cover
 - government intervention, 432–35
 - private health insurance, 432–35
- concertation procedure, health protection, 159
- ‘constitutional asymmetry’
 - policy, 5–7
- ‘constitutional asymmetry’, 79
- Constitutional Treaty, competition law, 332–34
- constraints, policy, 7–11
- constructivism, policy, 9
- continuing professional development (CPD), Directive 2005/36/EC, 613–18
- continuity of care, health professionals, 590
- Contracting Directive, Distance, e-health, 569–70
- contracting entities
 - public procurement, 404–12
 - SGEI, 404–12
- contractual arrangements
 - free movement of patients, 528
 - planned care, treatment abroad, 540–44
- contradictions, policy, 4–19
- cooperation initiatives, free movement of patients, 528
- coordination routes adjustments, treatment abroad, 535–38
- Court of First Instance (CFI)
 - GlaxoSmithKline, 663–66
 - pharmaceuticals market, 663–66
 - pricing and marketing, 663–66
- CPD, *see* continuing professional development
- CPMP, *see* Committee for Proprietary Medicinal Products
- cross-subsidies, policy, 12–19
- damage claims, competition law, 374–76
- data exclusivity, generic competition, pharmaceuticals, 650–51
- Data Protection Directive, e-health, 563–66, 576–79
- ‘*de minimis* Communication’, public procurement, 390–92
- decentralization of enforcement, competition law, 670–72
- decentralized/centralized licensing regime, pharmaceuticals market, 644–46
- deregulation, *see also* free movement of services; internal market policy, 25
- differential treatment of insurers
 - government intervention, 450
 - private health insurance, 450
- Directive 2004/27/EC, generic competition, 649–50
- Directive 2005/36/EC, 603–20
 - automatic recognition, 604–8
 - background, 603–4
 - common platforms, 609
 - CPD, 613–18
 - disciplinary matters, 619–20

- Directive 2005/36/EC (*cont.*)
 establishment vs. provision of services, 610–13
 general system, 608–9
 health professionals, 603–20
 practices allowed, 618
 professional qualifications, 603–20
 pursuit of the profession, 610–13
 qualifications recognition, 613–18
 qualifications, professional, 603–20
 quality, 613–18
 recognition, automatic, 604–8
 specific provisions, 606–8
 training, minimum conditions, 604–8
- disciplinary matters
 Directive 2005/36/EC, 619–20
 health professionals, 619–20
- discrimination, EU law, 25–26
- disease control, communicable, *see* communicable disease control
- Distance Contracting Directive, e-health, 569–70
- ‘Doctors’ Directives’, health professionals mobility, 592–93
- dominant position abuse, *see* abuse of dominant position
- dual pricing, GlaxoSmithKline, 663–66
- EACP, *see* ‘Europe against Cancer’ programme
- EC rules
 national health care, 393–416
 public procurement, 393–416
- ECDC, *see* European Centre for Disease Control; European Centre for Disease Prevention and Control
- ECHR, *see* European Convention on Human Rights
- ECJ, *see* European Court of Justice
- E-commerce Directive, e-health, 566–68
- economic activity, competition law, 319
- economic differences, Member States, health professionals, 589–90
- Economic Policy Committee (EPC), governance, 112–13
- e-Europe initiative, e-health, 572–73
- EFSA, *see* European Food Safety Authority
- e-health, 561–88
 applications, 561–62, 575–82
 competition law, 571–72
 conclusions, 587–88
 Contracting Directive, Distance, 569–70
 Data Protection Directive, 563–66, 576–79
 defining, 561–62
 Distance Contracting Directive, 569–70
 E-commerce Directive, 566–68
 e-Europe initiative, 572–73
 EHR, 575–79
 Electronic Signatures Directive, 570–71
 genetic data/tissue, 580–82
 health grids, 579–80
 health systems, policy impact, 572–75
 key area, EU legal and policy developments in health, 70–73
 legal challenges to promote, 575–87
 legal framework, 561–88
 legal instruments, 563–72
 liability legal framework, 585–87
 Medical Device Directives, 568–69
 overview, 70–73
 platforms, 575–79
 policy impact, 572–75
 Product Liability Directive, 586–87
 promoting, 575–87
 scope, 561–62
 status, 70–73
 telemedicine legal framework, 585–87
 telemedicine reimbursement criteria, 582–84
 telemedicine services, 574–75
 Working Group on Health Telematics, 573
- EHR, *see* electronic health records
- electronic health records (EHR), e-health, 575–79
- Electronic Signatures Directive, e-health, 570–71

- EMEA, *see* European Medicines Agency
 employment rights, EU law, 25–26
 entrepreneurial politics (concentrated/diffuse), 8–9
 environmental policy, public health policy, 234
 environmental tobacco smoke, tobacco control, 269–72
 EPC, *see* Economic Policy Committee
 equality
 EU Charter, 302
 fundamental rights, 302
 ERDF, *see* European Regional Development Fund
 erosion/protection of national social policies, 19–28
 ESF, *see* European Social Fund
 establishment vs. provision of services
 Directive 2005/36/EC, 610–13
 health professionals, 601–2
 ethical recruitment guidelines, health professionals, 622–23
 EU agenda, slow move of health care to the EU agenda, 106–21
 EU Charter
 equality, 302
 fundamental rights, 282–83
 health care law, 296–308
 health policy, 296–308
 personal data, 301–2
 solidarity, 303–8
 torture, 300–1
 EU institutions' roles, new governance, 226–28
 EU law, *see also* European Court of Justice (ECJ)
 cross-fertilization with governance, 131
 direct effect, 92–94
 discrimination, 25–26
 effects on health systems, 92–105
 employment rights, 25–26
 free movement of services, 94–101
 governance, cross-fertilization, 131
 health care law, 283–94
 health professionals, 73–75
 hybrid approaches, 82–83
 internal market, 94–101
 legal-policy patchwork, 92–105
 national social policies, 19–28
 supremacy, 92–94
 Tobacco Advertising Directive, 99–100
 tobacco control, 275–77
 ‘Europe against Cancer’ programme (EACP), tobacco control, 257–62
 European Centre for Disease Control (ECDC)
 development, 81–82
 role, 81–82
 shortcomings, 81–82
 European Centre for Disease Prevention and Control (ECDC), communicable disease control, 252–56
 European Commission
 competition law, 330–34
 political reform, 330–34
 European Convention on Human Rights (ECHR)
 abortion, 287–88
 health care law, 286–90
 reproductive technology, 288–90
 European Court of Justice (ECJ), *see also* EU law
 case-law, ECJ, 516–21
 competition law, 30–32, 322–25
 free movement of patients, 516–21
 free movement of patients, policy response to ECJ rulings, 521–27
 free movement of services, 30–32
 impact, 18–19
 interpreting law, 32–34
 jurisprudence, 27–28
 policy response to ECJ rulings, free movement of patients, 521–27
 role, 28–34
 SGEI, 326–29
 soft law, 34
 European Food Safety Authority (EFSA), 35–37
 accountability, 176–77
 cf. EMEA, 164–82
 core functions, 165–70
 governance, 171–81
 health protection, 161–62
 health systems, 181–82
 independence, 171–76
 industry's role, 180–81

- European Food Safety Authority (EFSA), (*cont.*)
 participation, 179–80
 politics of scientific advice, 165–70
 regulatory agencies, 135–37
 transparency, 177–79
- European Medicines Agency (EMA), 35–37
 accountability, 176–77
 centralized/decentralized licensing regime, 645–46
 cf. EFSA, 164–82
 core functions, 165–70
 governance, 171–81
 health protection, 159–60
 health systems, 181–82
 independence, 171–76
 industry's role, 180–81
 licensing regime, 645–46
 origin, 159–60
 participation, 179–80
 pharmaceuticals market, 645–46
 politics of scientific advice, 165–70
 regulatory agencies, 135–37
 transparency, 177–79
- European Regional Development Fund (ERDF), public health policy, 91–92
- European Social Charter, fundamental rights, 290–92
- European Social Fund (ESF), public health policy, 91–92
- European social model, welfare, 21–22
- European Union Agency for Fundamental Rights, health rights, 308–12
- Europeanization
 health protection, regulatory agencies, 154–64
 welfare, 20–21
- exclusionary abuse, competition law, 359–62
- FCA, *see* Finnish Competition Authority
- FCC, *see* French Competition Council
- financial transfers
 BUPA, 440–45
 government intervention, 437–47
 Ireland, 438–39, 440–45
 Netherlands, 438–39, 439–40
 Slovenia, 438–39, 445–47
- Finnish Competition Authority (FCA), competition law, 347
- foodstuffs
 EFSA, 161–62
 EFSA cf. EMA, 164–82
 European dimension, health protection, 157–62
 Platform on diet, nutrition and physical activity, 194
 priorities, balancing, 162–64
 SCF, 160–61
- Forum, Pharmaceutical, *see* Pharmaceutical Forum
- Foundation Trusts (FTs), competition law, 346–47
- fragmentation, pharmaceuticals market, 637–38
- free movement of patients, 509–60,
see also restrictions on movements of people; treatment abroad
 access arrangements, 529–51
 authorization, 530–35
 border regions access, 538–40
 case-law, 516–21
 challenges, 559
 community framework, 551–56,
 558–59
 conceptual construct, 511–14
 conclusions, 556–60
 contractual arrangements, 528
 contractual arrangements, planned care, 540–44
 cooperation initiatives, 528, 556
 coordination routes adjustments, 535–38
 ECJ case-law, 516–21
 fear of harm, 553–54
 governance, 511–28, 558
 informed choice, 554–55
 overview, 67–70
 planned care, contractual arrangements, 540–44
 policy response to ECJ rulings, 521–27
 private patients, 544
 retired people, 550–51
 safe, high-quality, efficient care, 551–56

- social security coordination, 514–16
- temporary stays abroad, 544–51
- tensions, 513–14
- treatment abroad, 529–44
- types, 529–51
- free movement of services, 461–508, *see also* deregulation; internal market; restrictions on movement of goods
 - barriers, 468–77
 - competition law, 101–2
 - conclusions, 505–8
 - ECJ, 30–32
 - economic nature of health care, 465–68
 - EU law, 94–101
 - generic (social services of general interest) approach, 502–5
 - health care as economic activity, 465–77
 - health systems approach, 499–502
 - HLG, 499–502
 - horizontal (internal market) approach, 497–99
 - internal market, 94–101
 - internal market approach, 497–99
 - justified restrictions, 477–93
 - key area, EU legal and policy developments in health, 64–67
 - legal certainty, 493–96
 - national actors, 493–96
 - Necessity Test, 479–82
 - overview, 64–67
 - policy challenge, 493–505
 - policy responses, EU level, 497–505
 - Proportionality Test, 482–93
 - public health policy, 232–33
 - sectoral (health systems) approach, 499–502
 - social and employment law, 102–5
 - social services of general interest approach, 502–5
 - types, *see also* deregulation; internal market; restrictions on movements of goods
 - unjustified restrictions, 477–93
- free movement of students, *see also* health professionals
 - quotas, 620–22
 - training access, 620–22
- French Competition Council (FCC), supply quotas, pharmaceuticals market, 668–69
- FTs, *see* Foundation Trusts
- fundamental rights, 282–314
 - conclusions, 312–14
 - ECHR, 286–90
 - equality, 302
 - EU Charter, 282–83
 - European Social Charter, 290–92
 - European Union Agency for Fundamental Rights, 308–12
 - health care law, 283–94, 294–312
 - key area, EU legal and policy developments in health, 54–56
 - Member States, 292–94
 - overview, 54–56
 - personal data, 301–2
 - solidarity, 303–8
 - torture, 300–1
- fundholding scheme, UK, competition law, 344–45
- funding
 - ERDF, 91–92
 - ESF, 91–92
 - public health policy, 90–92
- future
 - governance, 131–33
 - new governance, 224–30
 - public health policy, 277–80
- GCA, *see* German Competition Authority
- general directives
 - health professionals mobility, 597–603
 - shortcomings, 598–603
- general interest services, *see* services of general economic interest
- generic (social services of general interest) approach, free movement of services, 502–5
- generic competition, *see also* intra-brand competition; patent protection; pharmaceuticals market
 - abuse of dominant position, 655–59, 666
 - anti-competitive agreements, 660–61

- generic competition (*cont.*)
 - bio-similar medicines/products, 653–55
 - Commission Inquiry, 659–61
 - data exclusivity, 650–51
 - Directive 2004/27/EC, 649–50
 - marketing exclusivity, 651–53
 - pharmaceuticals market, 641–42, 649–61
 - Regulation 726/2004/EC, 649–50
 - regulatory pathway, 649–61
- generic medicines
 - competition law, 655–59
 - defining, 652–53
 - NCA, 371
 - pharmaceuticals policy and law, 371
 - pharmaceuticals pricing, 371
 - regulatory pathway, *see also* pharmaceuticals market
- genetic data/tissue, e-health, 580–82
- German Competition Authority (GCA), competition law, 347–48
- GlaxoSmithKline
 - abuse of dominant position, 666
 - CFI, 663–66
 - dual pricing, 663–66
 - marketing pathway, 663–66
 - pharmaceuticals market, 663–66
 - supply quotas, 666–69
- goods, restrictions on movements, communicable disease control, 249–50
- governance, *see also* new governance; regulatory agencies
 - After the Services Directive, 121–28
 - Bolkestein Directive, 121–28
 - cross-fertilization with EU law, 131
 - EFSA, 171–81
 - EMA, 171–81
 - EPC, 112–13
 - EU law, cross-fertilization, 131
 - free movement of patients, 511–28, 558
 - future, 131–33
 - Health Policy Forum, 115–16
 - HLG, 122–28, 130–31
 - HLPR, 116–21, 130–31
 - legal-policy patchwork, 105–28
 - new forms of, 34–42, 80
 - operationalization, 121–28
 - pharmaceutical industry priorities, 111–12
 - regulatory agencies, NMG, 135, 137–54
 - slow move of health care to the EU agenda, 106–21
 - soft law, 34–42, 80
- government intervention
 - benefits, 447–50
 - circumstances of, 430–37
 - complementary cover, 432–35
 - differential treatment of insurers, 450
 - financial transfers, 437–47
 - Ireland, 438–39, 440–45
 - legal challenges, 438–39
 - Netherlands, 431–33, 438–39, 439–40
 - private health insurance, 429–55
 - risk equalization schemes, 437–47
 - Slovenia, 438–39, 445–47
 - soft law, *see also* regulation
 - solvency requirements, 450–52
 - tax treatment, 453–55
 - types, 437–55
- Greek Syfait Case, pharmaceuticals market, 666–68
- health and safety, public health policy, 233–34
- health care as economic activity
 - barriers to free movement of services, 468–77
 - economic nature of health care, 465–68
 - free movement of services, 465–77
- health care law
 - Biomedicine Convention, 285–86
 - ECHR, 286–90
 - EU Charter, 296–308
 - fundamental rights, 283–94, 294–312
- health grids, e-health, 579–80
- health insurance market, competition law, 365–67
- health insurers, competition law, 342
- health policy, *see also* public health policy
 - competition law, 337–78

- EU Charter, 296–308
 - new governance, 191–93, 198–212
- Health Policy Forum, governance, 115–16
- health professionals, 589–634
 - ‘brain drain’, 622–23
 - communication, 599–600
 - conclusions, 632–34
 - continuity of care, 590
 - CPD, 613–18
 - Directive 2005/36/EC, 603–20
 - disciplinary matters, 619–20
 - distrust, 598–99
 - ‘Doctors’ Directives’, 592–93
 - economic differences, Member States, 589–90
 - establishment vs. provision of services, 601–2, 610–13
 - ethical recruitment guidelines, 622–23
 - EU law, 73–75, 589–634
 - free movement of students, 620–22
 - general directives, 597–603
 - Hungary, Working Time Directive, 628
 - information exchange, 600
 - key area, EU legal and policy developments in health, 73–75
 - Member States’ economic differences, 589–90
 - mobility, 591–623
 - non-discrimination rule, 600–1
 - overview, 73–75
 - payment issues, 602
 - practices allowed, 618
 - qualifications recognition, 613–18
 - qualifications, professional, 603–20
 - recruitment guidelines, ethical, 622–23
 - recruitment system failure, 622–23
 - reimbursement issues, 602
 - sectoral directives, 593–97
 - service provision vs. establishment of services, 601–2, 610–13
 - telemedicine, 603
 - training access, 620–22, 622–23
 - training, minimum conditions, 604–8
 - Working Time Directive, 623–32
- health protection
 - concertation procedure, 159
 - CPMP, 158–59
 - EFSA, 161–62
 - EMA, 159–60
 - European dimension, 157–62
 - Europeanization, 154–64
 - foodstuffs, European dimension, 157–62
 - pharmaceuticals policy and law, 158–59
 - pharmaceuticals, European dimension, 157–62
 - priorities, balancing, 162–64
 - regulatory agencies, 134–85, 154–64
 - SCF, 160–61
- health providers, competition law, 342
- health rights, European Union Agency for Fundamental Rights, 308–12
- health system reforms, competition law, 372–73
- health systems
 - best practices, 78–79
 - constrained competence, 79–80
 - EFSA, 181–82
 - e-health, policy impact, 572–75
 - EMA, 181–82
 - EU law effects, 92–105
 - evolving, 78
 - public procurement, 379–418
 - similarities, 12–19
 - state aid, 379–418
- health systems approach, free movement of services, 499–502
- High Level Group on Health Services and Medical Care (HLG)
 - free movement of services, 499–502
 - governance, 122–28, 130–31
 - new governance, 194–95
- ‘High Level Process of Reflection’ (HLPR), governance, 116–21, 130–31
- HLG, *see* High Level Group on Health Services and Medical Care
- HLPR, *see* ‘High Level Process of Reflection’

- horizontal (internal market) approach,
 - free movement of services, 497–99
- Hungary
 - health professionals, 628
 - Working Time Directive, 628
- IHR, *see* International Health Regulations
- imperium* principle, competition law, 341
- information exchange, health professionals, 600
- informed choice, treatment abroad, 554–55
- institutions' roles, EU, *see* EU institutions' roles
- insurance, private health, *see* private health insurance
- interest group politics (concentrated/concentrated), 8–9
- intergovernmentalism, policy, 9–10
- internal market, *see also* deregulation; free movement of services
 - competition law, 101–2
 - EU law, 94–101
 - free movement of services, 94–101
 - private health insurance, 419–60
 - public health policy, 235
 - public procurement, 389–93
 - regulating, 389–93
 - social and employment law, 102–5
 - Tobacco Advertising Directive, 99–100
- internal market approach, free movement of services, 497–99
- International Health Regulations (IHR), communicable disease control, 247–49
- international/national issues
 - relationship, public health policy, 231–32
- interpreting law, ECJ, 32–34
- intra-brand competition, *see also* generic competition
 - marketing pathway, 662–63
 - pharmaceuticals market, 642, 662–63
- Ireland
 - BUPA, 440–45
 - financial transfers, 438–39, 440–45
 - government intervention, 438–39, 440–45
 - private health insurance, 438–39, 440–45
 - risk equalization schemes, 438–39, 440–45
- key areas, EU legal and policy developments in health, 42
 - agencies, 45–49
 - competition law, 57–62
 - e-health, 70–73
 - free movement of patients, 67–70
 - free movement of services, 64–67
 - fundamental rights, 54–56
 - health professionals, 73–75
 - legal-policy patchwork, 42–45
 - pharmaceuticals policy and law, 75–77
 - private health insurance, 62–64
 - public health, 52–54
 - soft law, 49–51
- labelling, tobacco control, 265–69
- law, EU, *see* EU law
- legal certainty, free movement of services, 493–96
- legal challenges
 - government intervention, 438–39
 - private health insurance, 438–39
- legal instruments, e-health, 563–72
- legal-policy patchwork, 84–133
 - EU law effects on health systems, 92–105
 - governance, 105–28
 - key area, EU legal and policy developments in health, 42–45
 - overview, 42–45
 - predicament, 84–87
 - public health policy, 87–92
- liability legal framework, e-health, 585–87
- liberalization, policy, 25
- licensing regime
 - centralized/decentralized, 644–46
 - pharmaceuticals market, 644–46
 - regulatory pathway, 644–46

- lobbying, industry, tobacco control, 261–62, 268–69, 275–77
- local government policies, NCAs, 371–72
- majoritarian politics (diffuse/diffuse), 8–9
- market, internal, *see* internal market
- market-building policies, 2–3
- market-correcting policies, 2–3
- market-cushioning policies, 2–3
- marketing exclusivity, generic competition, pharmaceuticals, 651–53
- marketing pathway
 - GlaxoSmithKline, 663–66
 - implications, 669–72
 - intra-brand competition, 662–63
 - pharmaceuticals market, 661–72
 - pricing and marketing, 661–62
 - refusals to supply, 666–69
 - supply quotas, 666–69
- markets
 - competition law, 315–18
 - social solidarity, 315–18
- markets classification, private health insurance, 422
- Medical Device Directives, e-health, 568–69
- mobility, *see also* free movement
 - of patients; free movement of services
 - health professionals, 591–623
- Monti-Kroes package, *see* Altmark package
- national competition authorities (NCAs)
 - authority differences, 370
 - competition law, 367–76, 377
 - generic medicines, 371
 - local government policies, 371–72
 - pharmaceuticals policy and law, 371
 - pharmaceuticals pricing, 373
 - pressures, 369–72
- national regulation, pharmaceuticals market, 636–37
- national social policies
 - erosion/protection, 19–28
 - EU law, 19–28
 - protection/erosion, 19–28
- national/international issues
 - relationship, public health policy, 231–32
- NCAs, *see* national competition authorities
- Necessity Test, free movement of services, 479–82
- Netherlands
 - Bolkestein Directive, 431–33
 - competition law, 372–73
 - financial transfers, 438–39, 439–40
 - government intervention, 431–33, 438–39, 439–40
 - health system reforms, 372–73
 - private health insurance, 431–33, 438–39, 439–40
 - risk equalization schemes, 438–39, 439–40
- networks, EU
 - communicable disease control, 254–55
 - OMC, 218–20
- new governance
 - ambiguity of instruments, 212–24
 - Commission's role, 226–28
 - common health care objectives, 207
 - defining, 191–93
 - development, 190–91, 198–212
 - EU institutions' roles, 226–28
 - future, 224–30
 - health care on the agenda, 199–202
 - health policy, 191–93, 198–212
 - High Level Group on Health Services and Medical Care, 194–95
 - instruments' ambiguity, 212–24
 - mechanisms, 202–12
 - objectives, common health care, 207
 - objectives, overarching health care, 207–12
 - OMC, 193–98
 - overarching health care objectives, 207–12
 - persistence, 228–30

- new governance (*cont.*)
 - Platform on diet, nutrition and physical activity, 194, 218
 - regulatory agencies, 135, 137–54
 - resources, scarce, 225–26
 - scarce resources, 225–26
 - soft law, 188–91
 - usefulness, 228–30
 - varieties, 193
 - Working Time Directive, 204
- 'new modes of governance' (NMG), *see* new governance
- non-discrimination rule, health professionals, 600–1
- objectives
 - common health care, 207
 - public health policy, 89
- OMC, *see* open method of coordination
- open awards, award procedures, public procurement, 414–15
- open method of coordination (OMC)
 - as learning, 215–22
 - as soft law, 222–24
 - common health care objectives, 207
 - 'delivery gap', 214–15
 - indicators, 210–12
 - launch, 202–12
 - networks, EU, 218–20
 - new governance, 193–98
 - objectives, common health care, 207
 - objectives, overarching health care, 207–12
 - overarching health care objectives, 207–12
 - overview, 195–97
 - soft law, 193
 - soft law example, 39–42
 - steering instruments, 193
 - target setting, 220–22
- operationalization, governance, 121–28
- overarching health care objectives
 - new governance, 207–12
 - OMC, 207–12
- overview
 - agencies, 45–49
 - competition law, 57–62
 - e-health, 70–73
 - free movement of patients, 67–70
 - free movement of services, 64–67
 - fundamental rights, 54–56
 - health professionals, EU law, 73–75
 - legal-policy patchwork, 42–45
 - pharmaceuticals policy and law, 75–77
 - private health insurance, 62–64
 - public health, 52–54
 - soft law, 49–51
- Paris Court of Appeal, supply quotas, pharmaceuticals market, 668–69
- patchwork, legal-policy, *see* legal-policy patchwork
- patent certificate regime
 - pharmaceuticals market, 646–49
 - SPaC regime, 646–49
- patent protection, *see also* generic competition
 - clinical trials, 647–48
 - Commission Inquiry, 659–61
 - harmonization, remaining gaps, 648–49
 - pharmaceuticals market, 646–49
 - pharmacovigilance, 647–48
- patient information, Pharmaceutical Forum, 677–80
- patient mobility, *see* free movement of patients
- payment issues, health professionals, 602
- people, restrictions on movements, communicable disease control, 250–51
- personal data
 - EU Charter, 301–2
 - fundamental rights, 301–2
- Pharmaceutical Forum
 - patient information, 677–80
 - pharmaceuticals market, 672–80
 - pricing, 674–76
 - REAs, 676–77
- pharmaceutical industry
 - governance, 111–12
 - priorities, 111–12
- pharmaceuticals market, 681–82, *see also* generic competition; generic medicines; pharmaceuticals pricing

- bio-similar medicines/products, 653–55
- centralized/decentralized licensing regime, 644–46
- CFI, 663–66
- clinical trials, 647–48
- competition, 635–38
- competition consequences, 642–44
- competition law, 655–59
- competition law decentralization, 670–72
- competition parameters, 640–44
- competition policy ‘toolkit’, 638–39
- competition types, 640–44
- conclusions, 681–82
- data exclusivity, 650–51
- decentralization, competition law enforcement, 670–72
- EMA, 645–46
- forum, 672–80
- fragmentation, 637–38
- generic competition, 641–42, 649–61
- GlaxoSmithKline, 663–66
- Greek Syfait Case, 666–68
- intra-brand competition, 642, 662–63
- licensing regime, 644–46
- marketing exclusivity, 651–53
- marketing pathway, 661–72
- national regulation, 636–37
- parameters for competition, 640–44
- patent certificate regime, 646–49
- patent protection, 646–49
- patient information, 677–80
- Pharmaceutical Forum, 672–80
- pharmacovigilance, 647–48
- policy objectives, 635–38
- REAs, 676–77
- refusals to supply, 666–69
- regulatory pathway, 644–49
- SPaC regime, 646–49
- supply quotas, 666–69
- therapeutic competition, 640
- pharmaceuticals policy and law
 - CPMP, 158–59
 - EMA, 159–60
 - EMA cf. EFSA, 164–82
 - European dimension, health protection, 157–62
 - generic medicines, 371
 - key area, EU legal and policy developments in health, 75–77
 - NCAAs, 371
 - objectives, 635–38
 - overview, 75–77
 - priorities, balancing, 162–64
- pharmaceuticals pricing
 - CFI, 663–66
 - competition law, 373
 - dual pricing, 663–66
 - generic medicines, 371
 - NCAAs, 373
 - Pharmaceutical Forum, 674–76
 - pharmaceuticals market, 661–62, 663–66
- pharmacovigilance
 - patent protection, 647–48
 - pharmaceuticals market, 647–48
- planned care, contractual arrangements
 - free movement of patients, 540–44
 - treatment abroad, 540–44
- Platform on diet, nutrition and physical activity, new governance, 194, 218
- policy
 - ‘amenable mortality’, 5
 - challenges, 4–19
 - client politics (diffuse/concentrated), 8–9
 - common values and principles, 14–18
 - competition, 25
 - ‘constitutional asymmetry’, 5–7
 - constraints, 7–11
 - constructivism, 9
 - contradictions, 4–19
 - cross-subsidies, 12–19
 - deregulation, 25
 - entrepreneurial politics (concentrated/diffuse), 8–9
 - interest group politics (concentrated/concentrated), 8–9
 - intergovernmentalism, 9–10
 - liberalization, 25
 - majoritarian politics (diffuse/diffuse), 8–9
 - quality element, 80–81
 - rationalist perspectives, 8–9
 - soft law, 34–42